{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:44:30Z","timestamp":1793105070657,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1170236"],"award-info":[{"award-number":["OPP1170236"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"name":"PATH&apos;s Malaria Vaccine Initiative, joint funding with Bill and Melinda Gates Foundation with the same grant number."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The most advanced\n                    <jats:italic>P. falciparum<\/jats:italic>\n                    circumsporozoite protein-based malaria vaccine, RTS,S\/AS01 (RTS,S), confers partial protection but with antibody titers that wane relatively rapidly, highlighting the need to elicit more potent and durable antibody responses. Here, we elucidate crystal structures, binding affinities and kinetics, and in vivo protection of eight anti-NANP antibodies derived from an RTS,S phase 2a trial and encoded by three different heavy-chain germline genes. The structures reinforce the importance of homotypic Fab-Fab interactions in protective antibodies and the overwhelmingly dominant preference for a germline-encoded aromatic residue for recognition of the NANP motif. In this study, antibody apparent affinity correlates best with protection in an in vivo mouse model, with the more potent antibodies also recognizing epitopes with repeating secondary structural motifs of type I \u03b2- and Asn pseudo 3\n                    <jats:sub>10<\/jats:sub>\n                    turns; such insights can be incorporated into design of more effective immunogens and antibodies for passive immunization.\n                  <\/jats:p>","DOI":"10.1038\/s41467-021-21221-4","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T13:37:58Z","timestamp":1613569078000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Structural and biophysical correlation of anti-NANP antibodies with in vivo protection against P. falciparum"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5347-1936","authenticated-orcid":false,"given":"Tossapol","family":"Pholcharee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Oyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yevel","family":"Flores-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4708-5753","authenticated-orcid":false,"given":"Gonzalo","family":"Gonzalez-Paez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine L.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Volkmuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Emerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8860-0419","authenticated-orcid":false,"given":"C.","family":"Richter King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1414-6196","authenticated-orcid":false,"given":"Fidel","family":"Zavala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6469-2419","authenticated-orcid":false,"given":"Ian A.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"21221_CR1","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.3201\/eid2010.140619","volume":"20","author":"KH To\u00e9","year":"2014","unstructured":"To\u00e9, K. H. et al. Increased pyrethroid resistance in malaria vectors and decreased bed net effectiveness, Burkina Faso. Emerg. Infect. Dis. 20, 1691 (2014).","journal-title":"Emerg. Infect. Dis."},{"key":"21221_CR2","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1473-3099(19)30392-5","volume":"19","author":"WL Hamilton","year":"2019","unstructured":"Hamilton, W. L. et al. Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study. Lancet Infect. Dis. 19, 943\u2013951 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"21221_CR3","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(19)30937-7","volume":"393","author":"P Adepoju","year":"2019","unstructured":"Adepoju, P. RTS, S malaria vaccine pilots in three African countries. Lancet 393, 1685 (2019).","journal-title":"Lancet"},{"key":"21221_CR4","doi-asserted-by":"publisher","first-page":"21824","DOI":"10.1074\/jbc.M401979200","volume":"279","author":"JB Ancsin","year":"2004","unstructured":"Ancsin, J. B. & Kisilevsky, R. A binding site for highly sulfated heparan sulfate is identified in the N terminus of the circumsporozoite protein: significance for malarial sporozoite attachment to hepatocytes. J. Biol. Chem. 279, 21824\u201321832 (2004).","journal-title":"J. Biol. Chem."},{"key":"21221_CR5","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1084\/jem.20101488","volume":"208","author":"A Coppi","year":"2011","unstructured":"Coppi, A. et al. The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host. J. Exp. Med. 208, 341\u2013356 (2011).","journal-title":"J. Exp. Med."},{"key":"21221_CR6","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.chom.2007.10.002","volume":"2","author":"A Coppi","year":"2007","unstructured":"Coppi, A. et al. Heparan sulfate proteoglycans provide a signal to Plasmodium sporozoites to stop migrating and productively invade host cells. Cell Host Microbe 2, 316\u2013327 (2007).","journal-title":"Cell Host Microbe"},{"key":"21221_CR7","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/385336a0","volume":"385","author":"R M\u00e9nard","year":"1997","unstructured":"M\u00e9nard, R. et al. Circumsporozoite protein is required for development of malaria sporozoites in mosquitoes. Nature 385, 336 (1997).","journal-title":"Nature"},{"key":"21221_CR8","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1126\/science.2409595","volume":"228","author":"F Zavala","year":"1985","unstructured":"Zavala, F. et al. Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science 228, 1436\u20131440 (1985).","journal-title":"Science"},{"key":"21221_CR9","doi-asserted-by":"publisher","first-page":"8847","DOI":"10.1016\/j.vaccine.2011.09.098","volume":"29","author":"R Schwenk","year":"2011","unstructured":"Schwenk, R. et al. Immunization with the RTS, S\/AS malaria vaccine induces IFN-\u03b3+ CD4 T cells that recognize only discrete regions of the circumsporozoite protein and these specificities are maintained following booster immunizations and challenge. Vaccine 29, 8847\u20138854 (2011).","journal-title":"Vaccine"},{"key":"21221_CR10","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1093\/nar\/gkg081","volume":"31","author":"A Bahl","year":"2003","unstructured":"Bahl, A. et al. PlasmoDB: the Plasmodium genome resource. A database integrating experimental and computational data. Nucleic Acids Res. 31, 212\u2013215 (2003).","journal-title":"Nucleic Acids Res."},{"key":"21221_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/srep01990","volume":"3","author":"NM Bowman","year":"2013","unstructured":"Bowman, N. M. et al. Comparative population structure of Plasmodium falciparum circumsporozoite protein NANP repeat lengths in Lilongwe, Malawi. Sci. Rep. 3, 1990 (2013).","journal-title":"Sci. Rep."},{"key":"21221_CR12","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1126\/science.6204383","volume":"225","author":"JB Dame","year":"1984","unstructured":"Dame, J. B. et al. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 225, 593\u2013599 (1984).","journal-title":"Science"},{"key":"21221_CR13","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1126\/science.6204384","volume":"225","author":"V Enea","year":"1984","unstructured":"Enea, V. et al. DNA cloning of Plasmodium falciparum circumsporozoite gene: amino acid sequence of repetitive epitope. Science 225, 628\u2013630 (1984).","journal-title":"Science"},{"key":"21221_CR14","doi-asserted-by":"publisher","first-page":"4880","DOI":"10.1016\/j.vaccine.2010.05.033","volume":"28","author":"S Casares","year":"2010","unstructured":"Casares, S., Brumeanu, T.-D. & Richie, T. L. The RTS, S malaria vaccine. Vaccine 28, 4880\u20134894 (2010).","journal-title":"Vaccine"},{"key":"21221_CR15","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1056\/NEJMoa1207564","volume":"368","author":"A Olotu","year":"2013","unstructured":"Olotu, A. et al. Four-year efficacy of RTS, S\/AS01E and its interaction with malaria exposure. N. Engl. J. Med 368, 1111\u20131120 (2013).","journal-title":"N. Engl. J. Med"},{"key":"21221_CR16","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1515257","volume":"374","author":"A Olotu","year":"2016","unstructured":"Olotu, A. et al. Seven-year efficacy of RTS, S\/AS01 malaria vaccine among young African children. N. Engl. J. Med 374, 2519\u20132529 (2016).","journal-title":"N. Engl. J. Med"},{"key":"21221_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","volume":"386","author":"RTS, S.","year":"2015","unstructured":"RTS, S. Clinical Trial Partnerships. Efficacy and safety of RTS, S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31\u201345 (2015).","journal-title":"Lancet"},{"key":"21221_CR18","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/S1473-3099(15)00239-X","volume":"15","author":"MT White","year":"2015","unstructured":"White, M. T. et al. Immunogenicity of the RTS,S\/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect. Dis. 15, 1450\u20131458 (2015).","journal-title":"Lancet Infect. Dis."},{"key":"21221_CR19","doi-asserted-by":"publisher","unstructured":"Venkatraman, N. et al. Phase I assessments of first-in-human administration of a novel malaria anti-sporozoite vaccine candidate, R21 in matrix-M adjuvant, in UK and Burkinabe volunteers. Preprint at https:\/\/doi.org\/10.1101\/19009282 (2019).","DOI":"10.1101\/19009282"},{"key":"21221_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4161\/hv.6.1.10396","volume":"6","author":"SL Hoffman","year":"2010","unstructured":"Hoffman, S. L. et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum. Vaccin 6, 97\u2013106 (2010).","journal-title":"Hum. Vaccin"},{"key":"21221_CR21","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/nm.4110","volume":"22","author":"AS Ishizuka","year":"2016","unstructured":"Ishizuka, A. S. et al. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat. Med 22, 614\u2013623 (2016).","journal-title":"Nat. Med"},{"key":"21221_CR22","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/nm.4512","volume":"24","author":"NK Kisalu","year":"2018","unstructured":"Kisalu, N. K. et al. A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat. Med. 24, 408 (2018).","journal-title":"Nat. Med."},{"key":"21221_CR23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nm.4513","volume":"24","author":"J Tan","year":"2018","unstructured":"Tan, J. et al. A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein. Nat. Med. 24, 401 (2018).","journal-title":"Nat. Med."},{"key":"21221_CR24","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/s41591-020-0881-9","volume":"26","author":"R Murugan","year":"2020","unstructured":"Murugan, R. et al. Evolution of protective human antibodies against Plasmodium falciparum circumsporozoite protein repeat motifs. Nat. Med 26, 1135\u20131145 (2020).","journal-title":"Nat. Med"},{"key":"21221_CR25","doi-asserted-by":"publisher","first-page":"e1008373","DOI":"10.1371\/journal.ppat.1008373","volume":"16","author":"D Oyen","year":"2020","unstructured":"Oyen, D. et al. Structure and mechanism of monoclonal antibody binding to the junctional epitope of Plasmodium falciparum circumsporozoite protein. PLoS Pathog. 16, e1008373 (2020).","journal-title":"PLoS Pathog."},{"key":"21221_CR26","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1126\/science.aar5304","volume":"360","author":"K Imkeller","year":"2018","unstructured":"Imkeller, K. et al. Antihomotypic affinity maturation improves human B cell responses against a repetitive epitope. Science 360, 1358\u20131362 (2018).","journal-title":"Science"},{"key":"21221_CR27","doi-asserted-by":"publisher","first-page":"eaau8529","DOI":"10.1126\/sciadv.aau8529","volume":"4","author":"D Oyen","year":"2018","unstructured":"Oyen, D. et al. Cryo-EM structure of P. falciparum circumsporozoite protein with a vaccine-elicited antibody is stabilized by somatically mutated inter-Fab contacts. Sci. Adv. 4, eaau8529 (2018).","journal-title":"Sci. Adv."},{"key":"21221_CR28","doi-asserted-by":"publisher","first-page":"E10438","DOI":"10.1073\/pnas.1715812114","volume":"114","author":"D Oyen","year":"2017","unstructured":"Oyen, D. et al. Structural basis for antibody recognition of the NANP repeats in Plasmodium falciparum circumsporozoite protein. Proc. Natl Acad. Sci. USA 114, E10438\u2013E10445 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"21221_CR29","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.jmb.2019.12.029","volume":"432","author":"T Pholcharee","year":"2020","unstructured":"Pholcharee, T. et al. Diverse antibody responses to conserved structural motifs in Plasmodium falciparum circumsporozoite protein. J. Mol. Biol. 432, 1048\u20131063 (2020).","journal-title":"J. Mol. Biol."},{"key":"21221_CR30","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.immuni.2017.11.007","volume":"47","author":"G Triller","year":"2017","unstructured":"Triller, G. et al. Natural parasite exposure induces protective human anti-malarial antibodies. Immunity 47, 1197\u20131209. e1110 (2017).","journal-title":"Immunity"},{"key":"21221_CR31","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/infdis\/jiw237","volume":"214","author":"JA Regules","year":"2016","unstructured":"Regules, J. A. et al. Fractional third and fourth dose of RTS,S\/AS01 malaria candidate vaccine: a phase 2a controlled human malaria parasite infection and immunogenicity study. J. Infect. Dis. 214, 762\u2013771 (2016).","journal-title":"J. Infect. Dis."},{"key":"21221_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-019-3055-9","volume":"18","author":"Y Flores-Garcia","year":"2019","unstructured":"Flores-Garcia, Y. et al. Optimization of an in vivo model to study immunity to Plasmodium falciparum pre-erythrocytic stages. Malar. J. 18, 426 (2019).","journal-title":"Malar. J."},{"key":"21221_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-020-03181-0","volume":"19","author":"R Raghunandan","year":"2020","unstructured":"Raghunandan, R. et al. Characterization of two in vivo challenge models to measure functional activity of monoclonal antibodies to Plasmodium falciparum circumsporozoite protein. Malar. J. 19, 113 (2020).","journal-title":"Malar. J."},{"key":"21221_CR34","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1126\/science.aaz9356","volume":"367","author":"L Rouge","year":"2020","unstructured":"Rouge, L. et al. Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab. Science 367, 1224\u20131230 (2020).","journal-title":"Science"},{"key":"21221_CR35","first-page":"66","volume":"68","author":"L Schofield","year":"1990","unstructured":"Schofield, L. The circumsporozoite protein of Plasmodium: a mechanism of immune evasion by the malaria parasite? Bull. World Health Organ 68, 66\u201373 (1990).","journal-title":"Bull. World Health Organ"},{"key":"21221_CR36","doi-asserted-by":"publisher","first-page":"eaap8029","DOI":"10.1126\/sciimmunol.aap8029","volume":"3","author":"R Murugan","year":"2018","unstructured":"Murugan, R. et al. Clonal selection drives protective memory B cell responses in controlled human malaria infection. Sci. Immunol. 3, eaap8029 (2018).","journal-title":"Sci. Immunol."},{"key":"21221_CR37","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41590-018-0228-6","volume":"19","author":"IA Cockburn","year":"2018","unstructured":"Cockburn, I. A. & Seder, R. A. Malaria prevention: from immunological concepts to effective vaccines and protective antibodies. Nat. Immunol. 19, 1199\u20131211 (2018).","journal-title":"Nat. Immunol."},{"key":"21221_CR38","doi-asserted-by":"publisher","first-page":"e59018","DOI":"10.7554\/eLife.59018","volume":"9","author":"I Kucharska","year":"2020","unstructured":"Kucharska, I. et al. Structural ordering of the Plasmodium berghei circumsporozoite protein repeats by inhibitory antibody 3D11. eLife 9, e59018 (2020).","journal-title":"eLife"},{"key":"21221_CR39","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/328257a0","volume":"328","author":"DA Herrington","year":"1987","unstructured":"Herrington, D. A. et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 328, 257\u2013259 (1987).","journal-title":"Nature"},{"key":"21221_CR40","doi-asserted-by":"publisher","first-page":"S579","DOI":"10.1093\/clinids\/11.Supplement_3.S579","volume":"11","author":"RS Nussenzweig","year":"1989","unstructured":"Nussenzweig, R. S. & Nussenzweig, V. Antisporozoite vaccine for malaria: experimental basis and current status. Rev. Infect. Dis. 11, S579\u2013S585 (1989).","journal-title":"Rev. Infect. Dis."},{"key":"21221_CR41","doi-asserted-by":"publisher","unstructured":"Lewis, F. J. et al. Avid binding by B cells to the Plasmodium circumsporozoite protein repeat suppresses responses to protective subdominant epitopes. Preprint at https:\/\/doi.org\/10.1101\/2020.01.12.903682 (2020).","DOI":"10.1101\/2020.01.12.903682"},{"key":"21221_CR42","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1002\/art.38754","volume":"66","author":"YC Tan","year":"2014","unstructured":"Tan, Y. C. et al. Barcode-enabled sequencing of plasmablast antibody repertoires in rheumatoid arthritis. Arthritis Rheumatol. 66, 2706\u20132715 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"21221_CR43","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1093\/bioinformatics\/btk004","volume":"22","author":"JM Volpe","year":"2006","unstructured":"Volpe, J. M., Cowell, L. G. & Kepler, T. B. SoDA: implementation of a 3D alignment algorithm for inference of antigen receptor recombinations. Bioinformatics 22, 438\u2013444 (2006).","journal-title":"Bioinformatics"},{"key":"21221_CR44","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jchromb.2007.06.020","volume":"856","author":"U Ritz\u00e9n","year":"2007","unstructured":"Ritz\u00e9n, U., Rotticci-Mulder, J., Str\u00f6mberg, P. & Schmidt, S. R. Endotoxin reduction in monoclonal antibody preparations using arginine. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 856, 343\u2013347 (2007).","journal-title":"J. Chromatogr. B: Anal. Technol. Biomed. Life Sci."},{"key":"21221_CR45","doi-asserted-by":"publisher","first-page":"e111020","DOI":"10.1371\/journal.pone.0111020","volume":"9","author":"R Schwenk","year":"2014","unstructured":"Schwenk, R. et al. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice. PLoS ONE 9, e111020\u2013e111020 (2014).","journal-title":"PLoS ONE"},{"key":"21221_CR46","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/pro.2253","volume":"22","author":"NJ Anthis","year":"2013","unstructured":"Anthis, N. J. & Clore, G. M. Sequence-specific determination of protein and peptide concentrations by absorbance at 205 nm. Protein Sci. 22, 851\u2013858 (2013).","journal-title":"Protein Sci."},{"key":"21221_CR47","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jmb.2017.12.012","volume":"430","author":"LJ Bailey","year":"2018","unstructured":"Bailey, L. J. et al. Locking the elbow: Improved antibody Fab fragments as chaperones for structure determination. J. Mol. Biol. 430, 337\u2013347 (2018).","journal-title":"J. Mol. Biol."},{"key":"21221_CR48","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1107\/S0907444998010269","volume":"55","author":"JP Derrick","year":"1999","unstructured":"Derrick, J. P., Feavers, I. & Maiden, M. C. Use of streptococcal protein G in obtaining crystals of an antibody Fab fragment in complex with a meningococcal antigen. Acta Crystallogr. D: Biol. Crystallogr. 55, 314\u2013316 (1999).","journal-title":"Acta Crystallogr. D: Biol. Crystallogr."},{"key":"21221_CR49","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0076-6879(97)76066-X","volume":"276","author":"Z Otwinowski","year":"1997","unstructured":"Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307\u2013326 (1997).","journal-title":"Methods Enzymol."},{"key":"21221_CR50","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658\u2013674 (2007).","journal-title":"J. Appl. Crystallogr."},{"key":"21221_CR51","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D: Biol. Crystallogr. 66, 213\u2013221 (2010).","journal-title":"Acta Crystallogr. D: Biol. Crystallogr."},{"key":"21221_CR52","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr D: Biol. Crystallogr 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr D: Biol. Crystallogr"},{"key":"21221_CR53","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1107\/S0907444909042073","volume":"66","author":"VB Chen","year":"2010","unstructured":"Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D: Biol. Crystallogr. 66, 12\u201321 (2010).","journal-title":"Acta Crystallogr D: Biol. Crystallogr."},{"key":"21221_CR54","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/0263-7855(93)87010-3","volume":"11","author":"ML Connolly","year":"1993","unstructured":"Connolly, M. L. The molecular surface package. J. Mol. Graph 11, 139\u2013141 (1993).","journal-title":"J. Mol. Graph"},{"key":"21221_CR55","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1006\/jmbi.1994.1334","volume":"238","author":"IK McDonald","year":"1994","unstructured":"McDonald, I. K. & Thornton, J. M. Satisfying hydrogen bonding potential in proteins. J. Mol. Biol. 238, 777\u2013793 (1994).","journal-title":"J. Mol. Biol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21221-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21221-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21221-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T05:33:12Z","timestamp":1669959192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21221-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["21221"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-21221-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.07.18.210385","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,16]]},"assertion":[{"value":"20 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors T.P., D.O., Y.F.G., G.G.-P., Z.H., E.L., C.R.K., F.Z., and I.A.W. declare that they have no competing interests. K.L.W., W.V., and P.K. are employees of and own equity in Atreca, Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1063"}}